Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
about
Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeValidity of diagnostic coding within the General Practice Research Database: a systematic reviewDrugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.Clinical relevance and management of drug-related QT interval prolongation.Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?Comparative cardiac safety of low-dose thioridazine and low-dose haloperidolIn-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugsImproving postapproval drug safety surveillance: getting better information soonerDiagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database.Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomideUse of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.Moving towards better predictors of drug-induced torsades de pointes.Ventricular arrhythmias and nonsedating antihistaminesUrinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients.Failure of cetirizine and fexofenadine to prevent motion sickness.Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems.The effect of antihistamine cetirizine on ventricular repolarization in congenital long QT syndrome.Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
P2860
Q28544621-061F56B2-3E1B-480B-B139-DFC55507B662Q33689383-88F46D2D-BE3A-4E52-B5DC-E2309836A029Q34182020-3447A8A6-72C9-4283-967E-82DE7C259BD7Q34659165-A06FB73C-C5EA-4E6F-93C4-1FBEB1108D68Q34808260-D1A4731C-4D40-4B8D-91ED-90991AA62E7CQ34994268-0141B179-9470-46D8-8D68-34C5542E5653Q35048591-E08C8D5A-2C8F-4D33-804B-ECB2E12CC3E2Q35186542-A7E9E773-0134-4C07-A076-EC224E868350Q35803639-396CC6F4-3DB1-4E99-955D-73F899A04189Q35826214-081B2332-5918-455B-AACB-CEA64D4746EFQ36024396-DE1E1062-A45A-4C9E-B6BC-9E358DDB2D11Q36367834-2876F048-DD47-4AEE-945D-4C31EBD33654Q37000032-FC837CD3-31D6-4C58-91F2-9A7905B85E83Q37288597-72CD81F1-FFA9-4868-A4D0-51981A01A841Q38613100-041A5416-43D4-4B25-B085-C05369567547Q40900114-CE47DF34-B04C-4784-9A30-D849C9F4F358Q41255441-6AB8A124-BDAE-4123-908B-9228D3C0F3F0Q42561533-C772A630-B25A-45B7-BD33-EC80818E29CBQ44004672-22CE1B17-A1AF-4E23-B4E7-8F4323F79A27Q44292346-FF35A78A-3D26-4159-A343-607F87404C17Q46118138-E3F965C6-2B8A-419D-B47D-01097F0FE351Q50775824-FF933402-0814-4BB8-A2C4-0F35F4388450Q51910326-4140554C-2DB2-49CC-ABB0-5014AA8174B0
P2860
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@ast
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@en
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@nl
type
label
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@ast
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@en
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@nl
prefLabel
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@ast
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@en
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@nl
P2860
P3181
P1476
Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
@en
P2093
F J de Abajo
L A Rodríguez
P2860
P304
P3181
P356
10.1046/J.1365-2125.1999.00885.X
P407
P577
1999-03-01T00:00:00Z